Reduction of cardiovascular risk in chronic kidney disease by mineralocorticoid receptor antagonism

The Lancet Diabetes and Endocrinology

Volumn 3, Issue 12, 2015, Pages 993-1003

  Epstein, Murray ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ALISKIREN; BARDOXOLONE; EPLERENONE; EZETIMIBE; FINERENONE; MINERALOCORTICOID ANTAGONIST; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; SIMVASTATIN; SPIRONOLACTONE; MINERALOCORTICOID RECEPTOR;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); CONTROLLED CLINICAL TRIAL (TOPIC); DISEASE ASSOCIATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG WITHDRAWAL; END STAGE RENAL DISEASE; EVIDENCE BASED MEDICINE; HEART FAILURE; HEMODIALYSIS; HUMAN; HYPERKALEMIA; KIDNEY DYSFUNCTION; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PERITONEAL DIALYSIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; SIGNAL TRANSDUCTION; SUDDEN CARDIAC DEATH; ANIMAL; CARDIOVASCULAR DISEASES; CHRONIC KIDNEY FAILURE; COMPLICATION; PHYSIOLOGY; RISK FACTOR;

ALDOSTERONE; ANIMALS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; HUMANS; MINERALOCORTICOID RECEPTOR ANTAGONISTS; RECEPTORS, MINERALOCORTICOID; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS;

EID: 84947932518     PISSN: 22138587     EISSN: 22138595     Source Type: Journal    
DOI: 10.1016/S2213-8587(15)00289-2     Document Type: Review

References (103)

1. Ortiz A, Covic A, Fliser D, et al. Epidemiology, contributors to, and clinical trials of mortality risk in chronic kidney failure. Lancet 2014, 383:1831-1843. for the Board of the EURECA-m Working Group of ERA-EDTA.
2. Ojo A Addressing the global burden of chronic kidney disease through clinical and translational research. Trans Am Clin Climatol Assoc 2014, 125:229-246.
3. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004, 351:1296-1305.
4. Weiner D, Sarnak M Cardiovascular disease in patients with chronic kidney disease. Chronic kidney disease, dialysis and transplantation: a companion to Brenner and Rector's The Kidney 2010, 128-144. WB Saunders, Philadelphia, PA. 3rd edn. J. Himmelfarb, M.H. Sayegh (Eds.).
5. de Jager DJ, Grootendorst DC, Jager KJ, et al. Cardiovascular and noncardiovascular mortality among patients starting dialysis. JAMA 2009, 302:1782-1789.
6. Foley RN, Parfrey PS, Sarnak MJ Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998, 32(5 suppl 3):S112-S119.
7. Perkovic V, Ninomiya T, Arima H, et al. Chronic kidney disease, cardiovascular events, and the effects of perindopril-based blood pressure lowering: data from the PROGRESS study. J Am Soc Nephrol 2007, 18:2766-2772.
8. Chadban SJ, Briganti EM, Kerr PG, et al. Prevalence of kidney damage in Australian adults: the Ausdiab kidney study. J Am Soc Nephrol 2003, 14(suppl 2):131-138.
9. Imai E, Horio M, Iseki K, et al. Prevalence of chronic kidney disease (CKD) in the Japanese general population predicted by the MDRD equation modified by a Japanese coefficient. Clin Exp Nephrol 2007, 11:156-163.
10. Moody WE, Edwards NC, Madhani M, et al. Endothelial dysfunction and cardiovascular disease in early-stage chronic kidney disease: cause or association?. Atherosclerosis 2012, 223:86-94.
11. Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States 2011, US Renal Data System (USRDS), National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD.
12. Schiffrin EL, Lipman ML, Mann JFE Chronic kidney disease: effects on the cardiovascular system. Circulation 2007, 116:85-97.
13. Huybers S, Bindels RJM Vascular calcification in chronic kidney disease: new developments in drug therapy. Kidney Int 2007, 72:663-665.
14. Foley RN, Murray AM, Li S, et al. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol 2005, 16:489-495.
15. Moody WE, Edwards NC, Chue CD, et al. Arterial disease in chronic kidney disease. Heart 2013, 99:365-372.
16. Herzog CA, Mangrum JM, Passman R Sudden cardiac death and dialysis patients. Semin Dial 2008, 21:300-307.
17. Genovesi S, Valsecchi MG, Rossi E, et al. Sudden death and associated factors in a historical cohort of chronic haemodialysis patients. Nephrol Dial Transplant 2009, 24:2529-2536.
18. Herzog CA, Strief JW, Collins AJ, Gilbertson DT Cause-specific mortality of dialysis patients after coronary revascularization: why don't dialysis patients have better survival after coronary intervention?. Nephrol Dial Transplant 2008, 23:2629-2633.
19. Liu Y, Coresh J, Eustace JA, et al. Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition. JAMA 2004, 291:451-459.
20. Alborzi P, Patel N, Agarwal R Home blood pressures are of greater prognostic value than hemodialysis unit recordings. Clin J Am Soc Nephrol 2007, 2:1228-1234.
21. Kalantar-Zadeh K, Block G, Humphreys MH, et al. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int 2003, 63:793-808.
22. Aspirin for the prevention of cardiovascular disease: U.S. preventive services task force recommendation statement. Ann Intern Med 2009, 150:396-404. US Preventive Services Task Force.
23. Rosendorff C, Lackland DT, Allison M, et al. Treatment of hypertension in patients with coronary artery disease: a scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. Hypertension 2015, 65:1372-1407.
24. Jun M, Lv J, Perkovic V, Jardine MJ Managing cardiovascular risk in people with chronic kidney disease: a review of the evidence from randomized controlled trials. Ther Adv Chronic Dis 2011, 2:265-278.
25. Gupta J, Dominic EA Association between Inflammation and cardiac geometry in chronic kidney disease: findings from the CRIC Study. PLoS One 2015, 10:e0124772. the CRIC Study Investigators.
26. Shanahan CM, Crouthamel MH, Kapustin A, Giachelli CM Arterial calcification in chronic kidney disease: key roles for calcium and phosphate. Circ Res 2011, 109:697-711.
27. Flythe JE, Brunelli SM Blood pressure variability among chronic dialysis patients: recent advances in knowledge. Curr Opin Nephrol Hypertens 2015, 24:163-169.
28. Wanner C, Krane V, Marz W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005, 353:238-248.
29. Fellstrom BC, Jardine AG, Schmieder RE, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009, 360:1395-1407.
30. Strippoli GFL, Navaneethan SD, Johnson DW, et al. Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials. BMJ 2008, 336:645-651.
31. Epstein M, Vaziri ND Statins in the management of dyslipidemia associated with chronic kidney disease. Nat Rev Nephrol 2012, 8:214-223.
32. Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011, 377:2181-2192.
33. Cice G, Ferrara L, D'Andrea A, D'Isa S, et al. Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial. J Am Coll Cardiol 2003, 41:1438-1444.
34. Cice G, Di Benedetto A, D'Isa S, et al. Effects of telmisartan added to angiotensin-converting enzyme inhibitors on mortality and morbidity in hemodialysis patients with chronic heart failure a double-blind, placebo-controlled trial. J Am Coll Cardiol 2010, 56:1701-1708.
35. Zannad F, Kessler M, Lehert P, et al. Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of fosinopril and implications for future studies. Kidney Int 2006, 70:1318-1324.
36. Agarwal R, Sinha AD Cardiovascular protection with antihypertensive drugs in dialysis patients: a systematic review and meta-analysis. Hypertension 2009, 53:860-866.
37. Agarwal R Blood pressure and mortality among hemodialysis patients. Hypertension 2010, 55:762-768.
38. Dikow R, Hardt SE The uremic myocardium and ischemic tolerance: a world of difference. Circulation 2012, 125:1215-1216.
39. de Zeeuw D, Akizawa T, Audhya P, et al. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N Engl J Med 2013, 369:2492-2503.
40. Parving HH, Brenner BM, McMurray JJ, et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012, 367:2204-2213.
41. Pfeffer MA, Burdmann EA, Chen CY, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009, 361:2019-2032.
42. Funder JW Aldosterone and mineralocorticoid receptors: past, present and future. Endocrinology 2010, 151:5098-5102.
43. Wendler A, Albrecht C, Wehling M Nongenomic actions of aldosterone and progesterone revisited. Steroids 2012, 77:1002-1006.
44. Grossmann C, Gekle M New aspects of rapid aldosterone signaling. Mol Cell Endocrinol 2009, 308:53-62.
45. Dooley R, Harvey BJ, Thomas W Non-genomic actions of aldosterone: from receptors and signals to membrane targets. Mol Cell Endocrinol 2012, 350:223-234.
46. Williams JS Evolving research in nongenomic actions of aldosterone. Curr Opin Endocrinol Diabetes Obes 2013, 20:198-203.
47. Whaley-Connell A, Habibi J, Wei Y, et al. Mineralocorticoid receptor antagonism attenuates glomerular filtration barrier remodeling in the transgenic Ren2 rat. Am J Physiol Renal Physiol 2009, 296:F1013-F1022.
48. Whaley-Connell A, Habibi J, Nistala R, et al. Mineralocorticoid receptor-dependent proximal tubule injury is mediated by a redox-sensitive mTOR/S6K1 pathway. Am J Nephrol 2012, 35:90-100.
49. Shavit L, Lifschitz M, Epstein M Aldosterone blockade and the mineralocorticoid receptor in the management of chronic kidney disease: current concepts and emerging treatment paradigms. Kidney Int 2012, 81:955-968.
50. Epstein M Aldosterone blockade: an emerging strategy for abrogating progressive renal disease. Am J Med 2006, 119:912-919.
51. Epstein M, Williams GH, Weinberger M, et al. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type II diabetes. Clin J Am Soc Nephrol 2006, 1:940-951.
52. Sowers JR, Whaley-Connell A, Epstein M Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension. Ann Intern Med 2009, 150:776-783.
53. Epstein M Mineralocorticoid receptor antagonists: part of an emerging treatment paradigm for chronic kidney disease. Lancet Diabetes Endocrinol 2014, 2:925-927.
54. Bender SB, DeMarco VG, Padilla J, et al. Mineralocorticoid receptor antagonism treats obesity-associated cardiac diastolic dysfunction. Hypertension 2015, 65:1082-1088.
55. Joffe HV, Kwong RY, Gerhard-Herman MD, et al. Beneficial effects of eplerenone versus hydrochlorothiazide on coronary circulatory function in patients with diabetes mellitus. J Clin Endocrinol Metab 2007, 92:2552-2558.
56. Schmieder RE, Messerli FH, Garavaglia GE, et al. Dietary salt intake. A determinant of cardiac involvement in essential hypertension. Circulation 1988, 78:951-956.
57. Wang Q, Clement S, Gabbiani G, et al. Chronic hyperaldosteronism in a transgenic mouse model fails to induce cardiac remodeling and fibrosis under a normal-salt diet. Am J Physiol Renal Physiol 2004, 286:F1178-F1184.
58. Xue C, Siragy HM Local renal aldosterone system and its regulation by salt, diabetes, and angiotensin II type 1 receptor. Hypertension 2005, 46:584-590.
59. Aroor AR, Demarco VG, Jia G, et al. The role of tissue renin-angiotensin-aldosterone system in the development of endothelial dysfunction and arterial stiffness. Front Endocrinol (Lausanne) 2013, 4:161.
60. Gekle M, Grossmann C Actions of aldosterone in the cardiovascular system: the good, the bad, and the ugly?. Pflugers Arch 2009, 458:231-246.
61. N'Gankam V, Uehlinger D, Dick B, Frey BM, Frey FJ Increased cortisol metabolites and reduced activity of 11-beta-hydroxysteroid dehydrogenase in patients on hemodialysis. Kidney Int 2002, 61:1859-1866.
62. Guder G, Bauersachs J, Frantz S, et al. Complementary and incremental mortality risk prediction by cortisol and aldosterone in chronic heart failure. Circulation 2007, 115:1754-1761.
63. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999, 341:709-717.
64. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003, 348:1309-1321.
65. Zannad F, McMurray JJV, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011, 364:11-21.
66. Stripp B, Taylor AA, Bartter FC, et al. Effect of spironolactone on sex hormones in man. J Clin Endocrinol Metab 1975, 41:777-781.
67. Levitt JI Spironolactone therapy and amenorrhea. JAMA 1970, 211:2014-2015.
68. Garthwaite SM, McMahon EG The evolution of aldosterone antagonists. Mol Cell Endocrinol 2004, 217:27-31.
69. Hu X, Li S, McMahon EG, Lala DS, Rudolph AE Molecular mechanisms of mineralocorticoid receptor antagonism by eplerenone. Mini Rev Med Chem 2005, 5:709-718.
70. Kolkhof P, Borden SA Molecular pharmacology of the mineralocorticoid receptor: prospects for novel therapeutics. Mol Cell Endocrinol 2012, 350:310-317.
71. Kolkhof P, Nowack C, Eitner F Nonsteroidal antagonists of the mineralocorticoid receptor. Curr Opin Nephrol Hypertens 2015, 24:417-424.
72. Pitt B, Kober L, Ponikowski P, et al. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur Heart J 2013, 34:2453-2463.
73. Bakris GL, Agarwal R, Chan JC, et al. Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial. JAMA 2015, 314:884-894. for the Mineralocorticoid Receptor Antagonist Tolerability Study-Diabetic Nephropathy (ARTS-DN) Study Group.
74. Struthers A, Krum H, Williams GH A comparison of the aldosterone-blocking agents eplerenone and spironolactone. Clin Cardiol 2008, 31:153-158.
75. Sica DA Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis. Heart Fail Rev 2005, 10:23-29.
76. Roscioni SS, de Zeeuw D, Bakker SJL, et al. Management of hyperkalaemia consequent to mineralocorticoid-receptor antagonist therapy. Nat Rev Nephrol 2012, 8:691-699.
77. Yamaji M, Tsutamoto T, Kawahara C, et al. Effect of eplerenone versus spironolactone on cortisol and hemoglobin A(c) levels in patients with chronic heart failure. Am Heart J 2010, 160:915-921.
78. Weir RA, Tsorlalis IK, Steedman T, et al. Aldosterone and cortisol predict medium-term left ventricular remodelling following myocardial infarction. Eur J Heart Fail 2011, 13:1305-1313.
79. Swaminathan K, Davies J, George J, et al. Spironolactone for poorly controlled hypertension in type 2 diabetes: conflicting effects on blood pressure, endothelial function, glycaemic control and hormonal profiles. Diabetologia 2008, 51:762-768.
80. Davies JI, Band M, Morris A, et al. Spironolactone impairs endothelial function and heart rate variability in patients with type II diabetes. Diabetologia 2004, 47:1687-1694.
81. Macdonald JE, Kennedy N, Struthers AD Effects of spironolactone on endothelial function, vascular angiotensin converting enzyme activity, and other prognostic markers in patients with mild heart failure already taking optimal treatment. Heart 2004, 90:765-770.
82. Farquharson CA, Struthers AD Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation 2000, 101:594-597.
83. O'Keefe JH, Abuissa H, Pitt B Eplerenone improves prognosis in postmyocardial infarction diabetic patients with heart failure: results from EPHESUS. Diabetes Obes Metab 2008, 10:492-497.
84. Shiba N, Shimokawa H Chronic kidney disease and heart failure-bidirectional close link and common therapeutic goal. J Cardiol 2011, 57:8-17.
85. Pitt B, Anker SD, Böhm M, et al. Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease. Eur J Heart Fail 2015, 17:224-232.
86. Deo R, Yang W, Khan AM, et al. Serum aldosterone and death, end-stage renal disease, and cardiovascular events in blacks and whites: findings from the Chronic Renal Insufficiency Cohort (CRIC) Study. Hypertension 2014, 64:103-110.
87. Steigerwalt S, Zafar A, Mesiha N, Gardin J, Provenzano R Role of aldosterone in left ventricular hypertrophy among African-American patients with end-stage renal disease on hemodialysis. Am J Nephrol 2007, 27:159-163.
88. Drechsler C, Ritz E, Tomaschitz A, et al. Aldosterone and cortisol affect the risk of sudden cardiac death in haemodialysis patients. Eur Heart J 2013, 34:578-587.
89. Vardeny O, Wu DH, Desai A, et al. Influence of baseline and worsening renal function on efficacy of spironolactone in patients with severe heart failure. J Am Coll Cardiol 2012, 60:2082-2089.
90. Eschalier R, McMurray JJV, Swedberg K, et al. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function analyses of the EMPHASIS-HF Study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure). J Am Coll Cardiol 2013, 62:1585-1593.
91. Edner M, Benson L, Dahlström U, Lund LH Association between renin-angiotensin system antagonist use and mortality in heart failure with severe renal insufficiency: a prospective propensity score-matched cohort study. Eur Heart J 2015, 36:2318-2326.
92. Edwards NC, Steeds RP, Stewart PM, et al. Effect of spironolactone on left ventricular mass and aortic stiffness in early stage chronic kidney disease: a randomized controlled trial. J Am Coll Cardiol 2009, 54:505-512.
93. Matsumoto Y, Mori Y, Kageyama S, et al. Spironolactone reduces cardiovascular and cerebrovascular morbidity and mortality in hemodialysis patients. J Am Coll Cardiol 2014, 63:528-536.
94. Walsh M, Manns B, Garg AX, et al. The safety of eplerenone in hemodialysis patients: a noninferiority randomized controlled trial. Clin J Am Soc Nephrol 2015, published online July 2. 10.2215/CJN.12371214.
95. Hammer F Rationale and design of the Mineralocorticoid Receptor Antagonists in End-Stage Renal Disease Study (MiREnDa). Nephrol Dial Transplant 2014, 29:400-405.
96. Ruilope LM, Agarwal R, Chan JC, et al. Rationale, design, and baseline characteristics of ARTS-DN: a randomized study to assess the safety and efficacy of finerenone in patients with type II diabetes mellitus and a clinical diagnosis of diabetic nephropathy. Am J Nephrol 2015, 40:572-581.
97. Epstein M Hyperkalemia as a constraint to therapy with combination renin-angiotensin system blockade: the elephant in the room. J Clin Hypertens (Greenwich) 2009, 11:55-60.
98. Pitt B, Anker SD, Bushinsky DA, et al. Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial. Eur Heart J 2011, 32:820-828.
99. Epstein M, Reaven NL, Funk SE, McGaughey KJ, Oestreicher N, Knispel J Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors. Am J Managed Care 2015, 21(suppl):S212-S220.
100. Kosiborod M, Rasmussen HS, Lavin P, et al. Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial. JAMA 2014, 312:2223-2233.
101. Packham DK, Rasmussen HS, Lavin P, et al. Sodium zirconium cyclosilicate in hyperkalemia. N Engl J Med 2015, 372:222-231.
102. Weir MR, Bakris GL, Bushinsky DA, et al. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. N Engl J Med 2015, 372:211-221.
103. Bakris GL, Pitt B, Weir MR, et al. Effect of patiromer on serum potassium level in patients with hyperkalemia and diabetic kidney disease. The AMETHYST-DN randomized clinical trial. JAMA 2015, 314:151-161.